Displaying 45 (all) recruiting clinical trials.
-
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
This is a Phase 2 study testing whether a combination of TAS-102 and fruquintinib (a selective oral kinase inhibitor) is more effective and safer than ...
-
A Phase 2 Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
This is a phase 2 study to test whether the new study medicine, INCB123667 (CDK2 inhibitor), is safe and effective in patients with platinum-resistant ovarian ...
-
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726 (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
This is a pilot study to see whether biomarkers called Tumor Mutation Burden (TMB) and Gene Expression Profiling (GEP) can be used to study the ...
-
A Phase II randomized open-label multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg ... -
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
This is a phase II study, testing if lowering the dose of standard radiotherapy (RT) after standard chemotherapy medicines (Carboplatin & Etoposide) works well with fewer ...
-
Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients with Breast Cancer at High Risk of Recurrence
Scientific Rationale for the study design: Copper depletion is designed to be a complement to standard therapy to overcome resistance mechanisms hence it would be ... -
A Phase 2 Double-blind Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
This is a Phase 2 study testing how safe and effective a medicine called LY3537021 is when added to standard anti-nausea treatment. LY3537021 is a ...
-
An Open-label Multi-center Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
This is a Phase 2 study testing different doses of a medicine called HLX43 for patients with advanced non-small cell lung cancer (NSCLC). HLX43 is ...
-
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
Study TARA-002-101-Ph2 is an open-label Phase 2 study to investigate the safety and efficacy of TARA-002 administered intravesically in adults 18 years of age or ... -
TITLE: TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
This is a Phase II study testing a new treatment for people with locally advanced non-small cell lung cancer (LA-NSCLC). The goal of this study ...